Holen Sie sich die Stockscreener-App
7.55
0.80%
0.06
Handel nachbörslich:
7.62
0.07
+0.93%
Fennec Pharmaceuticals Inc Aktie (FENC) Neueste Nachrichten
(FRX) Risk-Controlled Trading Report (FRX:CA) - news.stocktradersdaily.com
How To Trade (FRX) (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Tumors - marketscreener.com
Fennec Pharmaceuticals Supports New Trial for Hearing Loss Prevention in Cancer Treatment - TipRanks
Fennec Pharma announces City of Hope PEDMARK trial in metastatic testicular tumors | FENC Stock News - Stock Titan
(FRX) Trading Performance and Risk Management (FRX:CA) - news.stocktradersdaily.com
Retail Surge: Will Fennec Pharmaceuticals Inc RV41 stock hit Wall Street targetsMarket Volume Report & Real-Time Sentiment Analysis - BỘ NỘI VỤ
Insider Sell: Rosty Raykov Sells 10,000 Shares of Fennec Pharmaceuticals Inc (FENC) - GuruFocus
Raykov Rosty sells Fennec Pharmaceuticals (FENC) shares for $75,400 - Investing.com
Raykov Rosty sells Fennec Pharmaceuticals (FENC) shares for $75,400 By Investing.com - Investing.com Australia
Fennec Pharmaceuticals Director Sells 10,000 Shares - TradingView
Dir Raykov Sells 10,000 ($75.4K) Of Fennec Pharmaceuticals Inc [FENC] - TradingView
Dir Raykov Files To Sell 10,000 Of Fennec Pharmaceuticals Inc [FENC] - TradingView
What hedge fund moves indicate for Fennec Pharmaceuticals Inc. (RV41) stockQuarterly Portfolio Report & Safe Investment Capital Preservation Plans - Newser
Will Fennec Pharmaceuticals Inc. (RV41) stock hit Wall Street targetsTake Profit & Fast Entry High Yield Tips - Newser
Can Fennec Pharmaceuticals Inc. (RV41) stock withstand sector downturns2025 Trade Ideas & Expert Verified Stock Movement Alerts - Newser
How analysts revise price targets for Fennec Pharmaceuticals Inc. (RV41) stockJuly 2025 Breakouts & Safe Entry Point Identification - Newser
(FENC) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Will Fennec Pharmaceuticals Inc. (RV41) stock benefit from Fed rate cutsDay Trade & Smart Allocation Stock Reports - Newser
Fennec Pharmaceuticals Reports Positive Results for PEDMARK® in Japan - MSN
Why Fennec Pharmaceuticals Inc. stock is popular among millennialsMarket Weekly Review & Daily Volume Surge Signals - Newser
(FRX) Technical Pivots with Risk Controls (FRX:CA) - news.stocktradersdaily.com
Is Fennec Pharmaceuticals Inc. stock resilient to inflationInflation Watch & Fast Entry Momentum Alerts - Newser
Fennec Pharmaceuticals (TSE:FRX) Stock Price Passes Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Can Fennec Pharmaceuticals Inc. stock attract ESG capital inflows2025 Bull vs Bear & Technical Pattern Based Buy Signals - Newser
Fennec Pharmaceuticals : Statement of Changes in Beneficial Ownership (Form 4) - marketscreener.com
Stocks in play: Fennec Pharmaceuticals Inc. - The Globe and Mail
Fennec Pharmaceuticals Inc Announces Positive Results from PEDMARK® Trial in Japan - TradingView
Wedbush on Fennec Pharmaceuticals Latest Japan Trial Results - marketscreener.com
Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power - Benzinga
Fennec Pharmaceuticals announces positive topline results - marketscreener.com
Fennec Pharmaceuticals Inc. Announces Positive Topline Results from Investigator-Initiated Clinical Study of Pedmark®? in Japan to Reduce Cisplatin-Induced Hearing Loss - marketscreener.com
Fennec Pharmaceuticals Reports Positive Top-line Results From Japan Trial - marketscreener.com
Fennec Pharmaceuticals Says its Phase 2/3 Trial of Pedmark in Japan Meets Primary Endpoint - marketscreener.com
Fennec’s pediatric hearing protection drug shows positive results in Japan By Investing.com - Investing.com Australia
Fennec Pharmaceuticals Brief: Announcing "Positive" Topline Results From Investigator-Initiated Clinical Study of PEDMARK in Japan to Reduce Cisplatin-Induced Hearing Loss - marketscreener.com
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss - The Manila Times
Is Fennec Pharmaceuticals Inc. (RV41) stock a buy before new product rolloutQuarterly Trade Report & Daily Stock Trend Reports - Newser
(FRX) Long Term Investment Analysis (FRX:CA) - news.stocktradersdaily.com
Brokerages Set Adherex Technologies Inc. (NASDAQ:FENC) Price Target at $13.33 - Defense World
(FRX) Technical Data (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference - The Globe and Mail
Loss-Making Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Expected To Breakeven In The Medium-Term - Yahoo Finance
Trend Tracker for (FRX) (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals highlights cisplatin ototoxicity risks - Traders Union
(FENC) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Why Some Analysts Are Raising Price Targets on Silkflex Polymers India LimitedStochastic Oscillator Alerts & Capital Efficiency Improvement - earlytimes.in
(FRX) Strategic Investment Report (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals Completes Full Debt Redemption, Strengthening Financial Position - MSN
Is Fennec Pharmaceuticals Inc. (RV41) stock attractive post correctionTrade Volume Report & Consistent Profit Focused Trading Strategies - newser.com
How Fennec Pharmaceuticals Inc. (RV41) stock performs in volatility spikesWatch List & Daily Entry Point Trade Alerts - newser.com
Will Fennec Pharmaceuticals Inc. stock benefit from commodity pricesJuly 2025 Sentiment & Free Risk Controlled Daily Trade Plans - newser.com
How Fennec Pharmaceuticals Inc. (RV41) stock trades pre earningsJuly 2025 Action & AI Enhanced Trading Alerts - newser.com
What dividend safety score for Fennec Pharmaceuticals Inc. stockJuly 2025 Fed Impact & High Yield Stock Recommendations - newser.com
Southpoint Capital Advisors LP sells Fennec Pharmaceuticals shares By Investing.com - Investing.com India
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):